Exelixis secured supplies of subcutaneous Keytruda for a planned Phase 3 colorectal cancer trial after completing the funding and contributor setup that includes Merck’s supply commitment. The arrangement supports ongoing trial logistics as immunotherapy combinations expand in colorectal indications. For stakeholders, the Keytruda supply pact reduces one of the major execution risks in late-stage oncology development—consistent access to antibody supply at scale—particularly for multicenter Phase 3 programs. The deal also reinforces Merck’s continuing role in combination regimens for large solid-tumor studies.